Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,877 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
2020 Korean guidelines for the management of metastatic prostate cancer.
Kim IH, Shin SJ, Kang BW, Kang J, Kim D, Kim M, Kim JY, Kim CK, Kim HJ, Maeng CH, Park K, Park I, Bae WK, Sohn BS, Lee MY, Lee JL, Lee J, Lim ST, Lim JH, Chang H, Jung JY, Choi YJ, Kim YS, Cho J, Joung JY, Park SH, Lee HJ. Kim IH, et al. Among authors: park i, park sh, park k. Korean J Intern Med. 2021 May;36(3):491-514. doi: 10.3904/kjim.2020.213. Epub 2021 Feb 10. Korean J Intern Med. 2021. PMID: 33561334 Free PMC article. Review.
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Lee JL, Park I, Park K, Park S, Ahn Y, Ahn JH, Kim TW, Ahn S, Song C, Hong JH, Kim CS, Ahn H. Lee JL, et al. Among authors: park s, park i, park k. J Cancer Res Clin Oncol. 2012 Apr;138(4):687-93. doi: 10.1007/s00432-012-1148-8. Epub 2012 Jan 12. J Cancer Res Clin Oncol. 2012. PMID: 22237457
Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.
Park K, Lee JL, Park I, Park S, Ahn Y, Ahn JH, Ahn S, Song C, Hong JH, Kim CS, Ahn H. Park K, et al. Among authors: park s, park i. Med Oncol. 2012 Dec;29(5):3291-7. doi: 10.1007/s12032-012-0227-7. Epub 2012 Mar 30. Med Oncol. 2012. PMID: 22460837
Langerhans cell histiocytosis followed by Hodgkin's lymphoma.
Park IS, Park IK, Kim EK, Kim S, Jeon SR, Huh JR, Suh CW. Park IS, et al. Korean J Intern Med. 2012 Dec;27(4):459-62. doi: 10.3904/kjim.2012.27.4.459. Epub 2012 Nov 27. Korean J Intern Med. 2012. PMID: 23269889 Free PMC article.
Response evaluation criteria in solid tumors response of the primary lesion in metastatic renal cell carcinomas treated with sunitinib: does the primary lesion have to be regarded as a target lesion?
Park I, Park K, Park S, Ahn Y, Ahn JH, Choi HJ, Jeong IG, Song C, Hong JH, Kim CS, Ahn H, Lee JL. Park I, et al. Among authors: park s, park k. Clin Genitourin Cancer. 2013 Sep;11(3):276-82. doi: 10.1016/j.clgc.2012.12.005. Epub 2013 Jan 17. Clin Genitourin Cancer. 2013. PMID: 23332873
A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer.
Kim YS, Sym SJ, Park SH, Park I, Hong J, Ahn HK, Park J, Cho EK, Lee WK, Chung M, Lee JH, Shin DB. Kim YS, et al. Among authors: park i, park sh, park j. Cancer Chemother Pharmacol. 2014 Jan;73(1):163-9. doi: 10.1007/s00280-013-2334-3. Epub 2013 Nov 8. Cancer Chemother Pharmacol. 2014. PMID: 24202666 Clinical Trial.
5,877 results